Increase of respiratory illnesses among children in Beijing, China, during the autumn and winter of 2023

Gong Cheng, Fang Huang, Luodan Suo, Xuejiao Guan, Lu Kang, Hui Xie, Geng Hu, Peng Yang, Quanyi WangEurosurveillance 2024 · DOI

Abstract

In 2023, through an ongoing respiratory pathogen surveillance system, we observed from mid-September onwards, an increase of respiratory illness among children aged ≤ 15 years presenting at hospital outpatient clinics in Beijing, China. Data indicated that illness was caused by multiple pathogens, predominantly Mycoplasma pneumoniae. Seasonality, periodicity and high prevalence of resistance to macrolide (30 of 30 strains sequenced with the A2063G mutation) were important characteristics of the M. pneumoniae epidemic, which resulted in a rise in consultations at specialised paediatric hospitals.

Introduction

In late 2023, reports of overwhelmed pediatric hospitals in Northern China drew significant international attention. While initial concerns focused on the potential emergence of a novel pathogen, data from the Beijing Center for Disease Prevention and Control (CDC) suggests a more complex epidemiological phenomenon. This surge in pediatric respiratory illnesses appears to be driven by the resurgence of known pathogens, particularly Mycoplasma pneumoniae (MP), following a three-year period of suppressed circulation due to COVID-19 non-pharmaceutical interventions (NPIs). This "susceptibility debt" likely contributed to a larger-than-usual pool of vulnerable children, leading to a massive "rebound" epidemic once restrictions were lifted.

Methods

The study utilized the Beijing Respiratory Pathogen Surveillance System, an established sentinel network of 35 hospitals across 16 districts. The system tracks Acute Respiratory Tract Infections (ARTIs), Influenza-Like Illness (ILI), and Community-Acquired Pneumonia.

Between 2019 and 2023, data from 1,689,123 patients were analyzed. A prospectively recruited subset (5–15 patients per hospital per week) underwent intensive laboratory testing using real-time PCR for 12 common respiratory pathogens. For MP-positive samples, molecular characterization included P1-genotyping and sequencing of the 23S rRNA gene to identify the A2063G mutation, a marker for macrolide resistance.

Results

The surveillance data revealed a dramatic increase in pediatric pneumonia cases. In children under 15, reported pneumonia cases rose by 92.3% from September (48,921 cases) to November 2023 (94,099 cases).

Trends in reported outpatients with ILI or pneumonia in Beijing (2019–2023), showing the significant surge in late 2023, particularly among children under 15.

The epidemic was characterized by a succession of pathogens rather than a single "superbug." MP predominated in September, followed by Adenovirus and Parainfluenza in October, and finally RSV and Influenza in November. Notably, genotype P1-1 of MP became dominant (74% of cases), up from 43.1% in 2021–2022.

A critical finding was the universal presence of the A2063G mutation in all 30 sequenced MP strains. This mutation confers high-level resistance to macrolides, the standard first-line treatment for pediatric MP infections. This resistance likely explains the high number of "refractory" cases requiring specialized hospital care, which further strained the healthcare system.

Discussion

The 2023 surge in Beijing highlights the impact of altered pathogen periodicity. MP epidemics typically occur in 1–3 year cycles; the four-year gap since the last major wave in 2019 allowed for a significant accumulation of susceptible individuals.

The 100% macrolide resistance rate presents a major public health challenge. With first-line antibiotics failing, clinicians face a dilemma, as alternative treatments like tetracyclines are generally avoided in young children due to potential side effects. Furthermore, the lack of rapid, point-of-care diagnostics at primary facilities led to an influx of patients at specialized pediatric hospitals, exacerbating the perception of a crisis. Future efforts should focus on improving primary care diagnostic capabilities and developing new pediatric-safe antimicrobial guidelines to manage resistant M. pneumoniae effectively.

Summary updated

Abstract

In 2023, through an ongoing respiratory pathogen surveillance system, we observed from mid-September onwards, an increase of respiratory illness among children aged ≤ 15 years presenting at hospital outpatient clinics in Beijing, China. Data indicated that illness was caused by multiple pathogens, predominantly <i>Mycoplasma pneumoniae</i>. Seasonality, periodicity and high prevalence of resistance to macrolide (30 of 30 strains sequenced with the A2063G mutation) were important characteristics of the <i>M. pneumoniae</i> epidemic, which resulted in a rise in consultations at specialised paediatric hospitals.
BibTeX
@inproceedings{cheng2024increase,
  author = {Gong Cheng and Fang Huang and Luodan Suo and Xuejiao Guan and Lu Kang and Hui Xie and Geng Hu and Peng Yang and Quanyi Wang},
  title = {{Increase of respiratory illnesses among children in Beijing, China, during the autumn and winter of 2023}},
  booktitle = {Eurosurveillance},
  year = {2024},
  doi = {10.2807/1560-7917.es.2024.29.2.2300704},
}
Figure